Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Millennium Partner in R&D and Supply Deal

SAN FRANCISCO, Oct. 24 – Millennium Pharmaceuticals entered a four-year R&D and volume discount supply agreement with Affymetrix, the companies announced Wednesday.

The deal includes co-development of gene expression array processes and applications for drug discovery and development, including next generation GeneChip technology applications.

Millennium, based in Cambridge, Mass., will transition its microarray use to Affymetrix’s GeneChip technology over the next year. Santa Clara-based Affymetrix will give Millennium preferred access and pricing to its gene expression platform, according to the companies.

Financial details of the agreement were not disclosed.

“Through this collaboration we will accelerate the evolution and use of our technology in drug development and health care,” said  Robert Lipshutz, vice president of corporate development and licensing at Affymetrix. “We plan to capture improvements to enhance our commercial offering.”

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.